E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary mamma carcinoma |
Brustkrebs |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006187 |
E.1.2 | Term | Breast cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Estimation of the complete response rate of invasive tumor cells in the breast confirmed by histological examinations |
|
E.2.2 | Secondary objectives of the trial |
Tumor response according to clinical criteria
Tumor response according to pathological criteria
Rate of breast-conserving surgery
Toxicity associated with the therapy
Disease free survival
Overall survival
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Women with histologically verified mamma carcinoma (assessment of estrogen and progesterone receptors, grading, negative HER-2/neu status)
• All receptor-negative mamma carcinoma starting from cT1c, all receptor-positive mamma carcinoma starting from cT3, cT4 includes inflammatory mamma carcinoma
• In case of cT2 and receptor-positivity, N+ is required and can also be detected with sentinel node biopsy
• In case of cT1c and receptor-positivity, a positive lymph node must be verified with sentinel node biopsy (pNsn+)
• Clinically and with an imaging technology (sonography or mammography) measurable primary tumor
• Sufficient bone marrow reserve: number of neutrophils >= 1,5 x 1000000000/L, number of thrombocytes >= 100 x 1000000000/L, hemoglobin >= 6,2 mmol/L
• Sufficient liver and renal function: bilirubin <=1 x upper limit of quantification (ULQ), ASAT (SGOT) and ALAT (SGPT) < 1,5 x ULQ, alcalic phosphatase < 1,5 x ULQ, Creatinine < 1 x ULQ (if creatinine > ULQ creatinine clearance must be > 60 mL/minute)
• Age-appropriate cardiologically normal findings as documented by ECG and LVEF (echocardiographical) assessments before beginning the therapy
• ECOG-performance-status of 0-2
• Age >=18 years
• Written informed consent of the patient including compliance of the patient regarding the therapy and the follow-up must be available before enrolment and documented according to the local regulations.
|
|
E.4 | Principal exclusion criteria |
• Pregnant or nursing women. Positive pregnancy test (urine or serum) within 7 days before registration
• Previous surgical, cytostatic or hormonal therapy (with exception of hormone substitution or contraception), no previous immune or radiation therapy
• Women with child bearing potency (menopause according to hormone status) without effective non-hormonal contraception (intra-uterine devices – spirals, condoms in combination with additional contraceptic measures, vasectomised partner) during the participation in the study and 6 months after the end of study therapy.
• Bilateral localisation of tumors
• Evidence of distant metastases after complete staging with chest X-ray, upper abdomen sonography, and/or CT and bone scintigraphy
• Pre-existing motor or sensor neurotoxicity > grade 2 (according to NCl criteria)
• Pre-existing cardiac disease not permitting the participation in this study (e.g. severe heart insufficiency or unstable angina pectoris, cardiac infarction within one year before study entry, uncontrolled hypertension, therapy resistant arrhythmia
• Significant neurological or psychiatric disease in the anamnesis (including psychotic disorders, dementia or seizures) compromising the understanding of the trial and consent to the trial.
• Drug abuse
• Active infection
• Florid ulcus, unstable diabetes mellitus
• Previously diagnosed tumor with exception of basalioma or in situ carcinoma of the cervix or other cancers having been treated curatively and having been followed by a disease-free interval of < 10 years.
• Chronic treatment with corticosteroids if not started > 6 months before study entry and at low doses (< 20 mg Methylprednisolone or equivalents)
• Clear contraindication for the application of corticosteroids
• Contraindication of the planned therapy:
- hypersensitivity to one of the trial drugs (Docetaxel, Cyclophosphamide and Epirubicine)
- extensive inflammatory condition of oral or gastrointestinal mucous membrane
• Lack of compliance
• Concomitant participation in other clinical trials
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Estimation of the complete response rate of invasive tumor cells in the breast confirmed by histological examinations |
Schätzung der Rate an durch histologische Untersuchung bestätigter kompletter Remission invasiver Tumore der Brust |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At end of therapy |
Bei Therapieende |
|
E.5.2 | Secondary end point(s) |
Tumor response according to clinical criteria determined by sonogrphy at surgery.
Tumor response according to pathological criteria determined by histology at surgery.
Rate of breast-conserving surgery
Toxicity associated with the therapy at each performed chemotherapy cycle.
Disease free survival until study end
Overall survival until study end
|
- Bestimmung des klinischen und pathologischen Tumoransprechens
- Bestimmung der Rate an brusterhaltenden Operationen
- Bestimmung der therapieassoziierten Toxizität
- Bestimmung des krankheitsfreien Überlebens und des Gesamtüberlebens
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At end of therapy and end of study |
Bei Therapieende und Studienende |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 16 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit |
Letzte Visite des letzten Patienten |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |